COVID-19 vaccination in dialysis and kidney transplant patients

被引：5

作者：

Sakhi, Hamza ^{[1
,2
]}

Chavarot, Nathalie ^{[3
]}

Attias, Philippe ^{[4
]}

El Karoui, Khalil ^{[1
,2
]}

Anglicheau, Dany ^{[3
]}

机构：

[1] Hop Univ Henri Mondor, Serv Nephrol & Transplantat, Federat Hosp Univ Innovat Therapy Immune Dis, Ctr Reference Maladie Rare Syndrome Nephrot Idiop, Creteil, France

[2] Univ Paris Est Creteil, Equipe 21, Inst Natl Sante & Rech Med Inserm U955, Inst Mondor Rech Biomed IMRB, Creteil, France

[3] Hop Univ Necker Enfants Malad, Serv Nephrol & Transplantat, Ctr Reference Maladie Rare MAREHA, Paris, France

[4] Hop Prive Nord Parisien, Dept Nephrol & Dialysis, Sarcelles, France

来源：

NEPHROLOGIE & THERAPEUTIQUE | 2021年 / 17卷 / 04期

关键词：

Antibodies; COVID-19; Peritoneal dialysis; Hemodialysis; SARS-CoV-2; Serology; Kidney transplantation; Vaccine; HEMODIALYSIS; RECIPIENTS; ANTIBODY;

D O I：

10.1016/j.nephro.2021.06.005

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Patients with end stage renal disease, including dialysis and kidney transplantation, have a high risk of severe COVID-19. In these populations, post-COVID-19 humoral response is prolonged until 6 months post-infection. However, post-vaccination humoral responses are frequently weak even when positive, notably in kidney transplant patients treated with belatacept. Actually, after 2 injectionos of mRNA vaccines, humoral response rates are 80-95% in dialysis patients, 30-50% in transplant patients, and about 5% in transplant patients treated with belatacept. These results have led to propose a 3rd injection of mRNA vaccine in dialysis and transplant patients in France. Numerous questions, regarding cellular responses, durability of response and clinical efficacy of vaccines remain in these high risk populations. (C) 2021 Societe francophone de nephrologie, dialyse et transplantation. Published by Elsevier Masson SAS. All rights reserved.

引用

页码：208 / 213

页数：6

共 35 条

[31] Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study [J].

Rozen-Zvi, Benaya ;

Yahav, Dafna ;

Agur, Timna ;

Zingerman, Boris ;

Ben-Zvi, Haim ;

Atamna, Alaa ;

Tau, Noam ;

Mashraki, Tiki ;

Nesher, Eviatar ;

Rahamimov, Ruth .

CLINICAL MICROBIOLOGY AND INFECTION, 2021, 27 (08) :1173.e1-1173.e4

[32] Kinetics of Anti?SARS-CoV-2 IgG Antibodies in Hemodialysis Patients Six Months after Infection [J].

Sakhi, Hamza ;

Dahmane, Djamal ;

Attias, Philippe ;

Kofman, Thomas ;

Bouvier, Magali ;

Lapidus, Nathanael ;

Fourati, Slim ;

El Karoui, Khalil .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (05) :1033-1036

[33] Kidney transplantation and COVID-19 renal and patient prognosis [J].

Toapanta, Nestor ;

Torres, Irina B. ;

Sellares, Joana ;

Chamoun, Betty ;

Seron, Daniel ;

Moreso, Francesc .

CLINICAL KIDNEY JOURNAL, 2021, 14 :21-29

[34] Factors associated with COVID-19-related death using OpenSAFELY [J].

Williamson, Elizabeth J. ;

Walker, Alex J. ;

Bhaskaran, Krishnan ;

Bacon, Seb ;

Bates, Chris ;

Morton, Caroline E. ;

Curtis, Helen J. ;

Mehrkar, Amir ;

Evans, David ;

Inglesby, Peter ;

Cockburn, Jonathan ;

McDonald, Helen, I ;

MacKenna, Brian ;

Tomlinson, Laurie ;

Douglas, Ian J. ;

Rentsch, Christopher T. ;

Mathur, Rohini ;

Wong, Angel Y. S. ;

Grieve, Richard ;

Harrison, David ;

Forbes, Harriet ;

Schultze, Anna ;

Croker, Richard ;

Parry, John ;

Hester, Frank ;

Harper, Sam ;

Perera, Rafael ;

Evans, Stephen J. W. ;

Smeeth, Liam ;

Ben Goldacre .

NATURE, 2020, 584 (7821) :430-+

[35] Experience with SARS-CoV-2 BNT162b2 mRNA vaccine in dialysis patients [J].

Yanay, Noa Berar ;

Freiman, Sarit ;

Shapira, Ma'anit ;

Wishahi, Samar ;

Hamze, Munir ;

Elhaj, Mohamad ;

Zaher, Maha ;

Armaly, Zaher .

KIDNEY INTERNATIONAL, 2021, 99 (06) :1496-1498

← 1 2 3 4 →